Conference Home

Scientific Agenda

Accommodations & Travel


The Canadian Immuno-Oncology Summit 2017 is a one day event being held Friday, September 15th 2017 in Toronto, Ontario. The Summit will be chaired by Dr. Sunil Verma and Dr. Rosalyn Juergens.

This year's program will cover a variety of important topics examining advances in immuno-oncology and also explore topics that pertain to clinical practice, adverse event management and the pharmacoeconomics of novel therapies. This event will draw from experts in immuno-oncology from across North America. 

Learning Objectives:

  • To review basic principles of immuno-oncology as well as key advances in different tumour sites
  • To discuss best practices and practical implications for patient management
  • To examine adverse event management of novel therapies
  • To discuss the pharmacoeconomics of these agents


Early Bird Price

Physicians: $129 CAD
Allied Healthcare Providers: $65 CAD
Students/Trainees: $39 CAD

Regular Price

Physicians: $179 CAD
Allied Healthcare Providers: $95 CAD
Students/Trainees: $50 CAD
Industry Badge: $500 CAD

About the Chair:

Dr. Sunil Verma, MD, MSEd, FRCPC is a Professor at the University of Calgary and Medical Director at the Tom Baker Cancer Centre. He completed his internal medicine and medical oncology training at the University of Alberta and then went on to a fellowship in breast cancer at the University of Toronto. He also completed his Master of Science in medical education from the University of California during his fellowship years.

Dr. Verma’s main clinical interests are in the treatment and management of breast cancer and lung cancer. He also has key research interests in neoadjuvant and endocrine treatment of breast cancer, reducing toxicity of systemic treatment, and developing novel therapies in breast and lung cancer. He has won numerous teaching awards and has also been recognized with many awards for his mentorship.

Dr. Verma has led and created a number of national and international educational projects in oncology. He is well published, including being first author in New England Journal of Medicine along with other prestigious journals and is recognized internationally for his research and education leadership in breast and lung cancer. He is a member of several professional societies including ASCO, the Canadian Association of Medical Oncologists, and the Canadian Medical Association.

Dr. Rosalyn Juergens, BS, MD, PhD is a Medical Oncologist at the Juravinski Cancer Centre in Hamilton, Ontario, Canada where she specializes in lung, stomach and esophageal cancers. She is also an Associate Professor in the Department of Oncology at McMaster University. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. She has several research interests. She has research expertise in functional imaging and has conducted phase I clinical trials with novel imaging probes. Her work in developmental therapeutics has focused on epigenetics, immuno-oncology and targeted therapies.

Member Comments. (0)

Oncology Clinical News

Celgene Settles Whistle-Blower Fraud Suit for $280 Million

(Bloomberg) July 25, 2017 - Celgene Corp. agreed to pay $280 million to resolve a whistle-blower’s claims the drugmaker used illegal marketing tactics to turn its Thalomid and Revlimid cancer drugs into blockbuster sellers, the U.S. said.
Read full article.

Eisai Submits Simultaneous Applications In The United States And Europe For Lenvatinib In Hepatocellular Carcinoma

(Eisai) July 25, 2017 - Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC).
Read full article.

Roche Gains CE Label Expansion For Companion Diagnostic To Identify ALK-positive Non-small Cell Lung Cancer Patients

(Yahoo! Finance) July 25, 2017 - Roche today announced that it has obtained a CE mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug ZYKADIA (ceritinib).
Read full article.

Powered by OBR Oncology